selectION has established an efficient technology platform to develop highly selective peptide blockers for ion channels. Their most advanced drug candidate is si-544 which is a best-in-class Kv1.3 blocker for treatment of effector memory T cell (TEM) driven diseases.The company is well positioned to expand its range of class-leading ion channelblockers by targeting additional potassium, sodium, calcium and chloride channels, which will lead to other clinical applications in pain management and oncology.

Biotechnology

Therapeutics

selectION

Antonius Schuh

Mark C. Wiggins

Elizabeth Anderson

Andreas Klostermann

Stephen Zaniboni

Leadership Team

Scientific Advisors

Teams at selectION

Leadership Team

Scientific Advisors